Upstate Active Clinical Trials

Study Title:

Celgene Protocol Number: CC-5013-NHL-007 - A phase 3, double-blind randomized study to compare the efficacy and safety of rituximab plus lenalidomide (cc-5013) versus rituximab plus placebo in subjects with relapsed/refractory indolent lymphoma

What is the purpose of the study?

This double-blind randomized, parallel group study will evaluate the efficacy and safety of lenalidomide (Revlimid, CC-5013) in combination with rituximab (MabThera/Rituxan) in patients with relapsed or refractory follicular lymphoma or marginal zone lymphoma. Patients will be randomized to receive either lenalidomide or placebo for twelve 28-day cycles in combination with rituximab. Anticipated time on study treatment is 1 year.

Upstate Institutional Review Board (IRB) Number:

570813

Study Phase:

III

Patient Age Group:

Adults

Principal Investigator:

Dorothy C Pan, MD

ClinicalTrials.Gov ID:

NCT01938001

For more information about this trial go to ClinicalTrials.Gov

Who can I contact for more information?

Name: Wendy S Barry
Phone: 315-464-8271
Email: barryw@upstate.edu

Return to Previous Page || Search Again